Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 801 to 825 of 1159 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
1126 decreased protein import into nucleus, translocation (GO:0000060) androgen receptor (PR:000004191) 2393: Androgen receptor nuclear transcriptional activity in genital-tubercle tissues, reduced
1127 decreased regulation of DNA binding (GO:0051101) androgen (CHEBI:50113) 2393: Androgen receptor nuclear transcriptional activity in genital-tubercle tissues, reduced
329 increased Amputation, Congenital (MESH:C565682) 591: Increased, amputations
1035 increased alpha-beta T cell receptor complex (GO:0042105) None
1036 increased gene conversion (GO:0035822) alpha-beta T cell receptor complex (GO:0042105) None
1052 occurrence gene conversion (GO:0035822) alpha-beta T cell receptor complex (GO:0042105) 2253: Gluten-reactive T cell receptors, generation
1151 abnormal Abnormality of cellular immune system (HP:0010987) alpha-beta T cell (CL:0000789) 2324: Increased of Treg/Th17 cell ratio
435 decreased signaling (GO:0023052) alpha-2A adrenergic receptor (PR:000001186) 849: Inhibition, Antgonism of NE receptor
1113 decreased G-protein coupled receptor signaling pathway (GO:0007186) alpha-1A adrenergic receptor (PR:000001183) 2370: Agonism binding, α1-Adrenoreceptor
1060 decreased retinoic acid biosynthetic process (GO:0002138) all-trans-retinoic acid (CHEBI:15367) 1881: Decreased, all-trans retinoic acid (atRA) concentration
486 decreased catalytic activity (GO:0003824) AKT kinase (PR:000029189) 973: KE5 : Decrease, AKT/eNOS activity
1148 occurrence Amyotrophic lateral sclerosis (HP:0007354) adult central nervous system (UBERON:6003623) 2416: human amyotrophic lateral sclerosis (ALS)
1108 increased Endometrial carcinoma (HP:0012114) adenosquamous carcinoma (MESH:D018196) 1070: Increased, adenosquamous carcinomas of endometrium
558 increased adenosquamous carcinoma (MESH:D018196) 1070: Increased, adenosquamous carcinomas of endometrium
567 increased Pituitary adenoma (HP:0002893) Adenoma (MESH:D000236) 1082: Increased, adenomas (pituitary)
366 increased Adenoma (MESH:D000236)
410 increased Carcinoma, Renal Cell (MESH:D002292) Adenoma (MESH:D000236) 713: Increase, Adenomas/carcinomas (renal tubular)
413 increased hepatocellular carcinoma (MESH:D006528) Adenoma (MESH:D000236) 719: Increase, hepatocellular adenomas and carcinomas
174 increased gene expression (GO:0010467) acyl-CoA desaturase (PR:000014497)
943 increased acute-phase response (GO:0006953) Acute phase proteins (N/A)
730 decreased activin receptor signaling pathway (GO:0032924) activin receptor complex (GO:0048179) None
729 decreased activin receptor signaling pathway (GO:0032924) activin complex (GO:0048180) None
1152 disrupted Abnormality of cellular immune system (HP:0010987) activated CD8-positive, alpha-beta T cell (CL:0000906) 2326: CTL cytotoxic activity disruption
982 decreased impaired synaptic plasticity (MP:0001900) actin cytoskeleton of dendritic spine (GO:0098938) None
1101 decreased dendritic spine morphogenesis (GO:0060997) actin cytoskeleton (GO:0015629) 2078: Loss of drebrin